Christopher J Wheeler

Summary

Affiliation: Cedars-Sinai Medical Center
Country: USA

Publications

  1. ncbi Dendritic cell vaccines and immunity in glioma patients
    Christopher J Wheeler
    MDNSI, Cedars Sinai Medical Center, 8631 W Third Street, Suite 800E, Los Angeles, CA 90048, USA
    Front Biosci 10:2861-81. 2005
  2. ncbi Vaccines for glioblastoma and high-grade glioma
    Christopher J Wheeler
    Maxine Dunitz Neurosurgical Institute, Department of Neurosurgery, Cedars Sinai Medical Center, 110 North George Burns Road, Davis 2097, Los Angeles, CA 90048, USA
    Expert Rev Vaccines 10:875-86. 2011
  3. ncbi Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients
    Christopher J Wheeler
    Maxine Dunitz Neurosurgical Institute, Department of Neurosurgery, Cedars Sinai Medical Center, Los Angeles, California, USA
    Cancer Res 68:5955-64. 2008
  4. ncbi Dendritic cell vaccines and obstacles to beneficial immunity in glioma patients
    Christopher J Wheeler
    Maxine Dunitz Neurosurgical Institute, Medical Center, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Curr Opin Mol Ther 7:35-47. 2005
  5. ncbi Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination
    Christopher J Wheeler
    Maxine Dunitz Neurosurgical Institute, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Clin Cancer Res 10:5316-26. 2004
  6. ncbi Thymic CD8+ T cell production strongly influences tumor antigen recognition and age-dependent glioma mortality
    Christopher J Wheeler
    Maxine Dunitz Neurosurgical Institute, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    J Immunol 171:4927-33. 2003
  7. ncbi HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells
    Gentao Liu
    Maxine Dunitz Neurosurgical Institute, Cedars-Sinai Medical Center, 8631 West Third Street, Suite 800E, Los Angeles, CA 90048, USA
    Cancer Res 64:4980-6. 2004
  8. ncbi Cytotoxic T cell targeting of TRP-2 sensitizes human malignant glioma to chemotherapy
    Gentao Liu
    Maxine Dunitz Neurosurgical Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
    Oncogene 24:5226-34. 2005
  9. ncbi Molecular and functional analysis of tyrosinase-related protein (TRP)-2 as a cytotoxic T lymphocyte target in patients with malignant glioma
    Gentao Liu
    Maxine Dunitz Neurosurgical Institute, Cedars Sinai Medical Center, Los Angeles, California, USA
    J Immunother 26:301-12. 2003
  10. ncbi Characterization of defective CD4-CD8- T cells in murine tumors generated independent of antigen specificity
    Robert M Prins
    Maxine Dunitz Neurosurgical Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
    J Immunol 172:1602-11. 2004

Research Grants

  1. EGFR activity in T cell-influenced glioma invasiveness & chemosensitivity
    Christopher Wheeler; Fiscal Year: 2007

Collaborators

Detail Information

Publications17

  1. ncbi Dendritic cell vaccines and immunity in glioma patients
    Christopher J Wheeler
    MDNSI, Cedars Sinai Medical Center, 8631 W Third Street, Suite 800E, Los Angeles, CA 90048, USA
    Front Biosci 10:2861-81. 2005
    ..Insight into the complex dynamics of immune-tumor interactions promises to extend this reach by delineating mechanisms of immune synergy with other forms of treatment...
  2. ncbi Vaccines for glioblastoma and high-grade glioma
    Christopher J Wheeler
    Maxine Dunitz Neurosurgical Institute, Department of Neurosurgery, Cedars Sinai Medical Center, 110 North George Burns Road, Davis 2097, Los Angeles, CA 90048, USA
    Expert Rev Vaccines 10:875-86. 2011
    ..Effective induction of antitumor immunity is consistently observed, and, in the latest trials, correlates with significant clinical improvement...
  3. ncbi Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients
    Christopher J Wheeler
    Maxine Dunitz Neurosurgical Institute, Department of Neurosurgery, Cedars Sinai Medical Center, Los Angeles, California, USA
    Cancer Res 68:5955-64. 2008
    ..As such, our findings offer unique opportunities to identify cellular and molecular components of clinically meaningful antitumor immunity in humans...
  4. ncbi Dendritic cell vaccines and obstacles to beneficial immunity in glioma patients
    Christopher J Wheeler
    Maxine Dunitz Neurosurgical Institute, Medical Center, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Curr Opin Mol Ther 7:35-47. 2005
    ..This progress promises to improve clinical vaccines for glioma, and perhaps for other cancers...
  5. ncbi Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination
    Christopher J Wheeler
    Maxine Dunitz Neurosurgical Institute, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Clin Cancer Res 10:5316-26. 2004
    ..To broaden the search for vaccine-induced benefits, we examined synergy of vaccines with conventional chemotherapy...
  6. ncbi Thymic CD8+ T cell production strongly influences tumor antigen recognition and age-dependent glioma mortality
    Christopher J Wheeler
    Maxine Dunitz Neurosurgical Institute, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    J Immunol 171:4927-33. 2003
    ....
  7. ncbi HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells
    Gentao Liu
    Maxine Dunitz Neurosurgical Institute, Cedars-Sinai Medical Center, 8631 West Third Street, Suite 800E, Los Angeles, CA 90048, USA
    Cancer Res 64:4980-6. 2004
    ..These data indicate that HER-2, gp100, and MAGE-1 could be used as tumor antigen targets for surrogate assays for antigen-specific CTLs or to develop antigen-specific active immunotherapy strategies for glioma patients...
  8. ncbi Cytotoxic T cell targeting of TRP-2 sensitizes human malignant glioma to chemotherapy
    Gentao Liu
    Maxine Dunitz Neurosurgical Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
    Oncogene 24:5226-34. 2005
    ..For the first time, we provide evidence that immunological targeting of tumor-associated antigen TRP-2 significantly increases sensitivity to chemotherapy...
  9. ncbi Molecular and functional analysis of tyrosinase-related protein (TRP)-2 as a cytotoxic T lymphocyte target in patients with malignant glioma
    Gentao Liu
    Maxine Dunitz Neurosurgical Institute, Cedars Sinai Medical Center, Los Angeles, California, USA
    J Immunother 26:301-12. 2003
    ..The authors' studies demonstrate that TRP-2 could be a useful antigen target for monitoring or developing immunotherapeutic strategies for glioma patients...
  10. ncbi Characterization of defective CD4-CD8- T cells in murine tumors generated independent of antigen specificity
    Robert M Prins
    Maxine Dunitz Neurosurgical Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
    J Immunol 172:1602-11. 2004
    ....
  11. ncbi Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma
    John S Yu
    Maxine Dunitz Neurosurgical Institute, Cedars Sinai Medical Center, 8631 West Third Street, Suite 800E, Los Angeles, CA 90048, USA
    Cancer Res 64:4973-9. 2004
    ..We demonstrate for the first time the ability of an active immunotherapy strategy to generate antigen-specific cytotoxicity in brain tumor patients...
  12. ncbi Cellular immunity in the treatment of brain tumors
    Christopher J Wheeler
    Cedars-Sinai Medical Center, Maxine Dunitz Neurosurgical Institute, Los Angeles, California, USA
    Clin Neurosurg 51:132-9. 2004
  13. ncbi T cells enhance stem-like properties and conditional malignancy in gliomas
    Dwain K Irvin
    Department of Neurosurgery, Maxine Dunitz Neurosurgical Institute, Cedars Sinai Medical Center, Los Angeles, California, United States of America
    PLoS ONE 5:e10974. 2010
    ..Many aspects of glioma CSCs (GSCs), however, have been characterized in non-physiological settings...
  14. ncbi Intratumoral T cell subset ratios and Fas ligand expression on brain tumor endothelium
    John S Yu
    The Marine Dunitz Neurosurgical Institute, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    J Neurooncol 64:55-61. 2003
    ....
  15. ncbi DCVax-Brain and DC vaccines in the treatment of GBM
    Christopher J Wheeler
    Maxine Dunitz Neurosurgical Institute, Department of Neurosurgery, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Expert Opin Investig Drugs 18:509-19. 2009
    ..DCVax-Brain composition and efficacy are not fully disclosed, although sponsors claim it is poised to critically test clinical DC vaccine efficacy in GBM patients...
  16. ncbi In situ adenoviral interleukin 12 gene transfer confers potent and long-lasting cytotoxic immunity in glioma
    Yunhui Liu
    Maxine Dunitz Neurosurgical Institute, Cedars Sinai Medical Center Los Angeles, California 90048, USA
    Cancer Gene Ther 9:9-15. 2002
    ..Based on IL-12's known ability to enhance Th1-type cytotoxic antitumor immune responses, we postulate our findings to be a result of localized induction of tumor immunity...
  17. ncbi Thymic function and output of recent thymic emigrant T cells during intracranial glioma progression
    Robert M Prins
    Department of Anatomy and Surgery, Virginia Commonwealth University/Medical College of Virginia, Richmond, VA, USA
    J Neurooncol 64:45-54. 2003
    ..Our findings may shed light on the significance of thymic function for anti-glioma immunity and the response to immunotherapeutic treatment paradigms...

Research Grants1

  1. EGFR activity in T cell-influenced glioma invasiveness & chemosensitivity
    Christopher Wheeler; Fiscal Year: 2007
    ....